Ron Bentsur bought $250K of NVCT stock

Ron Bentsur, Chairman & CEO, 10% of Nuvectis Pharma, Inc. (NVCT), bought 12,500 shares of NVCT stock worth $250K, per an SEC Form 4 filed Jul 1, 2026.

The shares came through a private deal, not the open market.

The trade happened on Jun 30, 2026, 1 day before it was made public.

NVCT has moved +10.0% since the trade date, from $18.39 to $20.23 (Nov 12, 2026 close).